Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia.

abstract：:Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematologi...

journal_title：Leukemia & lymphoma

authors： Sánchez-Castro J,Marco-Betés V,Gómez-Arbonés X,García-Cerecedo T,López R,Talavera E,Fernández-Ruiz S,Ademà V,Marugan I,Luño E,Sanzo C,Vallespí T,Arenillas L,Marco Buades J,Batlle A,Buño I,Martín Ramos ML,Blázquez Rios B

更新日期：2015-01-01 00:00:00

abstract：:Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections...

journal_title：Leukemia & lymphoma

authors： Tallman MS,Polliack A

更新日期：2009-10-01 00:00:00

abstract：:The MTT-based assay relies upon the cellular reduction of tetrazolium salts to their intensely colored formazans. The test is easy to perform in hematological malignancies and is adaptable for high throughput of samples, although there are some minor limitations in its application resulting from metabolic interference...

journal_title：Leukemia & lymphoma

authors： Hayon T,Dvilansky A,Shpilberg O,Nathan I

更新日期：2003-11-01 00:00:00

abstract：:The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of human leukocyte antigen-DR expressed on the majority of B-cell lymphomas and on normal B cells of most individuals. Hu1D10 mediates complement-mediated cytotoxicity, antibody-dependent cell-me...

journal_title：Leukemia & lymphoma

authors： Shi JD,Bullock C,Hall WC,Wescott V,Wang H,Levitt DJ,Klingbeil CK

更新日期：2002-06-01 00:00:00

abstract：:Tumor-infiltrating immune cells perform a crucial function in host immune reactions against diffuse large B-cell lymphoma (DLBCL). In this study, we have identified a subset of tumor-infiltrating FOXP3-positive regulatory T cells (Tregs) in the initial DLBCL biopsy specimens, and have evaluated their prognostic signif...

journal_title：Leukemia & lymphoma

authors： Lee NR,Song EK,Jang KY,Choi HN,Moon WS,Kwon K,Lee JH,Yim CY,Kwak JY

更新日期：2008-02-01 00:00:00

abstract：:The NK-like family of homeobox genes includes TLX1, TLX3 and NKX2-5, which are ectopically activated in distinct subsets of T-cell acute lymphoblastic leukemia (T-ALL) cells. Here we analysed their effect on the miR-17-92 cluster overexpressed in several types of cancer, including T-ALL. The pri-miR-17-92 polycistron ...

journal_title：Leukemia & lymphoma

authors： Nagel S,Venturini L,Przybylski GK,Grabarczyk P,Schmidt CA,Meyer C,Drexler HG,Macleod RA,Scherr M

更新日期：2009-01-01 00:00:00

abstract：:According to standard-protocols, real time quantitative RT-PCR (RQ-PCR) for quantification of BCR-ABL fusion transcripts in CML patients is performed with the construction of a standard curve for each run, each sample is analyzed at least in duplicate and 10-40 ml peripheral blood are processed. This approach is appro...

journal_title：Leukemia & lymphoma

authors： Röthlisberger B,Herklotz R,Hergersberg M,Stricker C,Bargetzi M,Huber AR

更新日期：2004-06-01 00:00:00

abstract：:The transduction of exogenous hepatocyte growth factor (HGF) genes to spleen T lymphocytes and the immune effects of syngeneic spleen graft on spleen lymphoma cells were studied in LEW/Sea rats. Three different systems were designed. (1) Six female rats and six male rats received irradiated spleen graft and were follo...

journal_title：Leukemia & lymphoma

authors： Nakatsuji T

更新日期：2003-01-01 00:00:00

abstract：:High dose chemotherapy with autologous stem cell transplantation (ASCT) improves outcomes in patients 65 years of age or less with multiple myeloma. Survival and costs in a cohort of 16 patients who received melphalan and prednisone as part of a clinical trial were compared with those of 36 patients referred to our ce...

journal_title：Leukemia & lymphoma

authors： Kouroukis CT,O'Brien BJ,Benger A,Marcellus D,Foley R,Garner J,Ingram C,Haines P,Henderson-O'Connor N,Meyer R

更新日期：2003-01-01 00:00:00

abstract：:High-dose melphalan therapy with peripheral blood stem cell (PBSC) transplantation is a standard treatment for younger patients with untreated multiple myeloma that results in high overall and complete response (CR) rates, and improved event-free and overall survival compared with standard chemotherapy alone. Inductio...

journal_title：Leukemia & lymphoma

authors： Oakervee H,Popat R,Cavenagh JD

更新日期：2007-10-01 00:00:00

abstract：:Primary gynecologic myeloid sarcomas are rare, and their diagnosis is often difficult. Differential diagnosis includes lymphomas and carcinomas of the gynecologic tract. We report the clinical, morphological, immunohistochemical and cytogenetic features of two cases of chloromas of the female genital tract, which prog...

journal_title：Leukemia & lymphoma

authors： Hernández JA,Navarro JT,Rozman M,Ribera JM,Rovira M,Bosch MA,Fantova MJ,Mate JL,Millá F

更新日期：2002-11-01 00:00:00

abstract：:Among 318 cases of non-Hodgkin's lymphoma (NHL) treated in our unit, 145 (45.6%) had primary extranodal NHL (PE-NHL). The stomach was the most common site (42.1%), followed by the PE-NHL of the head and neck region. Histologically aggressive histologies (65.5% intermediate and 20.7% high grade) predominated. 89.6% of ...

journal_title：Leukemia & lymphoma

authors： Economopoulos T,Asprou N,Stathakis N,Papageorgiou E,Dervenoulas J,Xanthaki K,Raptis S

更新日期：1996-03-01 00:00:00

abstract：:Immune suppression is a hallmark of multiple myeloma (MM), but data on soluble factors involved in the fate of immune effector cells are limited. The CXCR3-binding chemokine monokine induced by interferon-gamma (MIG/CXCL9) has been associated with tumor progression, immune escape, and angiogenesis in several malignanc...

journal_title：Leukemia & lymphoma

authors： Bolomsky A,Schreder M,Hübl W,Zojer N,Hilbe W,Ludwig H

更新日期：2016-11-01 00:00:00

abstract：:The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predict...

journal_title：Leukemia & lymphoma

authors： Akwaa F,Liesveld J

更新日期：2013-10-01 00:00:00

abstract：:Chromosome aberrations affecting 3q27 are among the most frequent non-random abnormalities in non-Hodgkin's lymphomas (NHL), especially the diffuse, large cell type. Recently, an association between BCL6 rearrangement and frequent extranodal lesions, rare bone marrow infiltration and a favorable clinical outcome was r...

journal_title：Leukemia & lymphoma

authors： Ohshima A,Miura I,Hashimoto K,Takahashi N,Utsumi S,Nimura T,Saito M,Miki T,Hirosawa S,Miura AB

更新日期：1997-10-01 00:00:00

abstract：:Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evalua...

journal_title：Leukemia & lymphoma

authors： Clark Schneider KM,Banks PM,Collie AM,Lanigan CP,Manilich E,Durkin LM,Hill BT,Hsi ED

更新日期：2016-07-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

journal_title：Leukemia & lymphoma

authors： Sidiqi MH,Gertz MA

更新日期：2019-02-01 00:00:00

abstract：:Out of 75 consecutive elderly AML patients who did not receive anti-leukemic treatment (52 pts) or failed to respond to differentiating agent (23 pts), 6 patients had survivals of 13.2 to 98 months with treatment restricted to supportive care. This cut-point is far longer than the median survival of the 235 elderly pa...

journal_title：Leukemia & lymphoma

authors： Baudard M,Legrand O,Marie JP,Zittoun R

更新日期：1999-08-01 00:00:00

abstract：:We performed double autologous PBSCT in one fulminantly relapsed ATL patient. Cryopreserved PBSCs containing tumour cells were thawed, and CD34+ cells were selected for by immunomagnetic beads, with the aim of decreasing the number of re-infused tumour cells. The patient received 0.72x10(6) and 0.90x10(6) CD34+ cells/...

journal_title：Leukemia & lymphoma

authors： Watanabe J,Kondo H,Hatake K

更新日期：2001-09-01 00:00:00

abstract：:A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was ...

journal_title：Leukemia & lymphoma

authors： Hornberger J,Reyes C,Shewade A,Lerner S,Friedmann M,Han L,Gutierrez H,Satram-Hoang S,Keating MJ

更新日期：2012-02-01 00:00:00

abstract：:In this study we compared rates of apoptosis, survival and metabolic activity from CML peripheral blood neutrophils with peripheral blood and bone marrow neutrophils from healthy volunteer donors and studied the influence of the disease stage and of cytokines including G-CSF, GM-CSF and IL-1beta on these parameters. Q...

journal_title：Leukemia & lymphoma

authors： Gisslinger H,Kurzrock R,Wetzler M,Tucker S,Kantarjian H,Robertson B,Talpaz M

更新日期：1997-03-01 00:00:00

abstract：:A new Ph1-positive acute lymphoblastic leukemia cell line, designated as ALL/MIK, has been developed from a patient with Ph1-positive acute leukemia. The ALL/MIK cells showed an immunophenotype of common ALL with rearranged JH and Jk genes. The ALL/MIK cells showed no M-bcr rearrangement using Southern blot analysis w...

journal_title：Leukemia & lymphoma

authors： Higa T,Okabe M,Kunieda Y,Kodama S,Itaya T,Kurosawa M,Sakurada K,Maekawa I,Shoji M,Kasai M

更新日期：1994-01-01 00:00:00

abstract：:Immunotherapy in the form of allogeneic stem cell transplantation (SCT) plays an instrumental role in the treatment of acute myeloid leukemia (AML), with non-transplant modalities of immunotherapy including checkpoint blockade now being actively explored. Here, we provide an overview of the graft versus leukemia (GVL)...

journal_title：Leukemia & lymphoma

authors： Knorr DA,Goldberg AD,Stein EM,Tallman MS

更新日期：2019-12-01 00:00:00

abstract：:Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

journal_title：Leukemia & lymphoma

authors： Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

更新日期：2011-04-01 00:00:00

abstract：:Classical Hodgkin lymphoma (cHL) is highly treatable with chemotherapy alone or combined modality therapy. High dose therapy and autologous stem cell transplant is considered standard of care for patients who relapse. For patients who relapse following transplant or who are not candidates for high dose therapy, progno...

journal_title：Leukemia & lymphoma

authors： Wildes TM,Bartlett NL

更新日期：2009-04-01 00:00:00

abstract：:We have studied the effect of dimethyl-sulfoxide(DMSO)-induced granulocytic differentiation on the sensitivity of HL-60 cells to various cytotoxic topoisomerase II inhibitors: (i) undifferentiated HL-60 cells are highly sensitive to etoposide, while differentiated HL-60 cells are 700-1000 fold resistant to etoposide, ...

journal_title：Leukemia & lymphoma

authors： Gieseler F,Boege F,Biersack H,Spohn B,Clark M,Wilms K

更新日期：1991-01-01 00:00:00

abstract：:We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on acute myeloid leukemia (AML) and B-lineage acute lymphoid leukemia (B-ALL) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for AML cells and IL-3 and IL-7 for ALL cells. Each molecule was added daily and cell ...

journal_title：Leukemia & lymphoma

authors： Defard M,Lemoine FM,Bonnet ML,Baillou C,Isnard F,Najman A,Guigon M

更新日期：1997-11-01 00:00:00

abstract：:Treatment results of 47 pregnant women with Hodgkin's disease (HD) are analyzed using data reported in the literature since 1960. Twenty-three of the patients were treated with radiation during pregnancy and 17 of the 23 patients (74%) were reported to be long term disease-free survivors. All of these pregnancies resu...

journal_title：Leukemia & lymphoma

authors： Yahalom J

更新日期：1990-01-01 00:00:00

abstract：:Primary myelosarcomas, also called leukemia cutis, granulocytic sarcomas or chloromas, are rare extramedullary manifestations of acute myeloid leukemia (AML) which precede bone marrow involvement. Skin infiltration was the most frequent localization associated with a myelomonocytic differentiation. Although first remi...

journal_title：Leukemia & lymphoma

authors： Reinhardt D,Creutzig U

更新日期：2002-03-01 00:00:00

abstract：:B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells are refractory to many of the signals which activate normal B cells but are stimulated to proliferate by tumor necrosis factor (TNF). Cell signalling by TNF is mediated in part by the induction of the transcription factor families AP-1 and NF-k...

journal_title：Leukemia & lymphoma

authors： Jabbar SA,Hoffbrand AV,Wickremasinghe RG

更新日期：1995-06-01 00:00:00